group (due to higher HIV incidence) did not lead to 'replacement' by individuals from 1 the low-activity group. 2
The model was represented by the following set of coupled, ordinary differential 3 equations (within the deterministic framework). The state variables and symbols are 4 shown in Figure 1 , and defined in Tables 1 and S1 . 5 6   Table S1: Table of 
HIV Transmission
In this model, HIV transmission occurs as a result of sex between men. The likelihood of 1 an individual having a sexual partnership with an individual in a given compartment was 2 proportional to the number of individuals in that compartment (proportional mixing). 3
The mixing term is described as follows, where P represents the population of a given 4 compartment, and N the total model population: 5
The activity level (high-or low-activity) of the individuals governed their potential 6 number of sexual partners. Condom use and transmission risk varied by compartment. 7
The likelihood of HIV transmission between an infected and uninfected male partner, 8 per relationship, per year was defined as τ and could be reduced by condom use ( or 9 by PrEP use ( ) (equations 1-3,6). ART use was assumed to reduce transmission to zero. 10
Inherent in this transmission model is the assumption that transmission risk can be 11 stratified into CD4 dependent groupings, which is employed frequently in HIV 12 transmission models. Similarly, we assumed that partnership mixing was proportional to 13 sub-population size. This assumption may be more accurate in a regional model 14 compared to a national model, but still is only an approximation of typically complex 15 interconnected sexual networks, potentially with activity-based assortment. We also 16 assumed that condom use proportionately decreases risk of transmission across all 17 group evenly and consistently. Similarly, we assume that individuals who are diagnosedwith HIV have a reduction in 'overall risk' which we denoted as reduction in transmission 1 risk, separate from number of partners. 2 3
PrEP and Antiretroviral Treatment 4
In this model, individuals could move into compartments corresponding to HIV 5 'prophylaxis' with PrEP (daily tenofovir/emtricitabine), and also compartments 6 corresponding to antiretroviral therapy. Regarding PrEP use, our baseline assumption 7 was a 44% reduction in risk of transmission, which was reflected in the transmission risk 8 term but not the activity ('number of partners'). We also assessed scenarios of variable 9
PrEP efficacy up to 99%, which may correspond to improved adherence [12] . We did not 10 model the possibility of the introduction of resistance, the magnitude of which in 11 studies has remained small, but could on a population-based scale represent a 12 significant attenuator of effectiveness. In addition, we also assumed that there was no 13 risk compensation with PrEP. Risk compensation has not been observed in organized 14 trials [13] . We also assumed that patients who stop ART were on treatment sufficiently 15 long enough to have recovered a robust CD4 count, and thus they enter into a 16 corresponding compartment of diagnosed/HIV positive. We assumed that patients on 17 treatment with ART have no chance of transmitting virus. 18
19

Calibration 20
This model was calibrated to historical conditions shown in (Table A1 , Figure S1 ), 21 derived from local public health data on HIV infection rate and mortality rate, wherepopulation specific values (Toronto MSM) were estimated based on regional rates and 1 historical population proportions. Monte Carlo sampling was employed for calibration, 2 where parameters that were varied (ART on-treatment rates, reduction in risky sexual 3 behavior after diagnosis, mortality in those with AIDS, combined condom use/efficacy, 4 and ART cessation rate) in a random fashion over defined ranges (Table 1) 
Cost Effectiveness Analysis 6
We chose to evaluate the cost of PrEP introduction from a health-systems perspective. 7
We used Canadian-based data (Table 1) to estimate the costs associated with HIV-8 related clinical care (for those on and off treatment), ART and PrEP related drug costs, as 9 well as diagnostic testing costs. We calculated costs at each time step of the model and 10 these were summed and discounted at a rate of 3% per annum. All values were shown 11 in CAD. 12
In order to determine cost-effectiveness, we also estimated the total quality-adjusted 13 life years (QALYs) gained with different interventions. Using established quality of liferatios, we determined the total quality adjusted life years, calculated at each time step, 1 and compared years gained with an intervention compared to the baseline scenario. We 2 did not extrapolate our model over longer than 20 years, and thus our estimated 3 incremental quality adjusted life years may be an underestimate of the true value. We 4 also discounted QALYs at a rate of 3% per annum. 5
Using our health care related costs and QALYs we determined the incremental cost-6 effectiveness, shown as the ratio of (total incremental costs)/(incremental QALYS) in 7 post-intervention groups compared to baseline groups. These are shown in Figure 2 . 8 9 
